HRP20140307T1 - Citotoksiäśna sredstva koja sadrže nove derivate tomamicina i njihova upotreba u terapiji - Google Patents
Citotoksiäśna sredstva koja sadrže nove derivate tomamicina i njihova upotreba u terapiji Download PDFInfo
- Publication number
- HRP20140307T1 HRP20140307T1 HRP20140307TT HRP20140307T HRP20140307T1 HR P20140307 T1 HRP20140307 T1 HR P20140307T1 HR P20140307T T HRP20140307T T HR P20140307TT HR P20140307 T HRP20140307 T HR P20140307T HR P20140307 T1 HRP20140307 T1 HR P20140307T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- conjugate
- cell
- compound
- agent
- Prior art date
Links
- UQVNRKBFAXNOGA-LWTNMJDUSA-N (E)-tomaymycin Chemical class CO[C@H]1NC2=CC(O)=C(OC)C=C2C(=O)N2C\C(=C\C)C[C@@H]12 UQVNRKBFAXNOGA-LWTNMJDUSA-N 0.000 title 1
- 229940127089 cytotoxic agent Drugs 0.000 title 1
- 239000002254 cytotoxic agent Substances 0.000 title 1
- 231100000599 cytotoxic agent Toxicity 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 12
- 239000011230 binding agent Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims 3
- 239000005556 hormone Substances 0.000 claims 3
- 229940088597 hormone Drugs 0.000 claims 3
- 125000005647 linker group Chemical group 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims 2
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 2
- POVMPWRYMPKDCR-KYJUHHDHSA-N (6as)-3-[[3-[[(6as)-8-ethylidene-2-methoxy-11-oxo-7,9-dihydro-6ah-pyrrolo[2,1-c][1,4]benzodiazepin-3-yl]oxymethyl]-5-(3-aminopropoxy)phenyl]methoxy]-8-ethylidene-2-methoxy-7,9-dihydro-6ah-pyrrolo[2,1-c][1,4]benzodiazepin-11-one Chemical compound N1=C[C@@H]2CC(=CC)CN2C(=O)C(C=C2OC)=C1C=C2OCC1=CC(OCCCN)=CC(COC2=CC3=C(C(N4CC(C[C@H]4C=N3)=CC)=O)C=C2OC)=C1 POVMPWRYMPKDCR-KYJUHHDHSA-N 0.000 claims 1
- WMZYAQQKYLKWGI-UHFFFAOYSA-N 1-hydroxypyrrolidine-2,5-dione 4-(pyridin-2-yldisulfanyl)butanoic acid Chemical compound ON1C(=O)CCC1=O.OC(=O)CCCSSC1=CC=CC=N1 WMZYAQQKYLKWGI-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- WODNFCXCOFBOSS-PXLJZGITSA-N CN(CCCC=1C=C(C=C(C=1)COC1=CC\2=C(C(N3[C@H](/C=N/2)CC(C3)=CC)=O)C=C1OC)COC1=CC\2=C(C(N3[C@H](/C=N/2)CC(C3)=CC)=O)C=C1OC)C(=O)OC(C)(C)C Chemical compound CN(CCCC=1C=C(C=C(C=1)COC1=CC\2=C(C(N3[C@H](/C=N/2)CC(C3)=CC)=O)C=C1OC)COC1=CC\2=C(C(N3[C@H](/C=N/2)CC(C3)=CC)=O)C=C1OC)C(=O)OC(C)(C)C WODNFCXCOFBOSS-PXLJZGITSA-N 0.000 claims 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims 1
- 102000014429 Insulin-like growth factor Human genes 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108010074338 Lymphokines Proteins 0.000 claims 1
- 102000008072 Lymphokines Human genes 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 claims 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims 1
- 229940094957 androgens and estrogen Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 229940047120 colony stimulating factors Drugs 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 125000002228 disulfide group Chemical group 0.000 claims 1
- 229940014144 folate Drugs 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000009257 reactivity Effects 0.000 claims 1
- 239000003270 steroid hormone Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- XSIXXACWIYMCKZ-ACHIHNKUSA-N tert-butyl N-[3-[2,6-bis[[(6aS)-8-ethylidene-2-methoxy-11-oxo-7,9-dihydro-6aH-pyrrolo[2,1-c][1,4]benzodiazepin-3-yl]oxymethyl]pyridin-4-yl]oxypropyl]carbamate Chemical compound C(C)(C)(C)OC(=O)NCCCOC1=CC(=NC(=C1)COC1=CC\2=C(C(N3[C@H](/C=N/2)CC(C3)=CC)=O)C=C1OC)COC1=CC\2=C(C(N3[C@H](/C=N/2)CC(C3)=CC)=O)C=C1OC XSIXXACWIYMCKZ-ACHIHNKUSA-N 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Claims (15)
1. Spoj, naznačen time što ga se bira iz sljedećeg spiska:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
kao i odgovarajući merkapto derivati,
ili njihovi farmaceutski prihvatljiv soli, hidrati, ili hidratirane soli, ili polimorfne kristalne strukture tih spojeva ili njihovi optički izomeri, racemati, dijastereomeri ili enantiomeri.
2. Spoj, naznačen time što ga se bira iz sljedećeg spiska:
• 8,8′-[4-(3-tert-butoksikarbonilaminopropiloksi)-2,6-piridinediilbis(metilenoksi)]bis[(S)-2-et-(E)-iliden-7-metoksi-1,2,3,11a-tetrahidro-5H-pirolo[2,1-c][1,4]benzodiazepin-5-on];
• 8,8′-[5-(3-aminopropiloksi)-1,3-benzenediilbis(metilenoksi)]bis[(S)-2-et-(E)-iliden-7-metoksi-1,2,3,11a-tetrahidro-5H-pirolo[2,1-c][1,4]banzodiazepin-5-on];
• 8,8′-[5-(N-metil-3-tert-butoksikarbonilaminopropil)-1,3-benzenediilbis(metilenoksi)]bis[(S)-2-et-(E)-iliden-7-metoksi-1,2,3,11a-tetrahidro-5H-pirolo[2,1-c][1,4]benzodiazepin-5-on].
3. Konjugat, naznačen time što sadrži jedan ili više spojeva u skladu s patentnim zahtjevom 1 ili 2, kovalentno vezanih na sredstvo za vezanje na stanicu preko povezujuće skupine jedne ili više spojnice.
4. Konjugat u skladu s patentnim zahtjevom 3, naznačen time što je navedena povezujuća skupina tiolna, sulfidna ili disulfidna skupina.
5. Konjugat u skladu s patentnim zahtjevom 3, naznačen time što je navedena povezujuća skupina -S- ili -S-S-.
6. Konjugat u skladu s patentnim zahtjevom 3 do 5, naznačen time što sredstvo za vezanje na stanicu se modificira modificirajućim sredstvom kako bi se povećala reaktivnost sredstva za vezanje na stanicu prema povezujućoj skupini spojnice.
7. Konjugat u skladu s patentnim zahtjevom 6, naznačen time što je modificirajuće sredstvo N-sulfosukcinimidil-4-(5-nitro-2-piridilditio)butanoat (SSNPB), sukcinimidil-4-[N-maleimidometil]cikloheksan-1-karboksilat (SMCC) ili N-hidroksisukcinimidni ester 4-(2-piridilditio)butanske kiseline (SPDB).
8. Konjugat u skladu s patentnim zahtjevom 3 do 7 naznačen time što se navedeno sredstvo za vezanje na stanicu bira između protutijela ili fragmenta protutijela koji sadrži najmanje jedno vežuće mjesto, limfokina, hormona, čimbenika rasta, molekula za prijenos nutrijenata ili bilo koje druge molekule ili tvari koja se veže na stanicu.
9. Konjugat u skladu s patentnim zahtjevom 3 do 8, naznačen time što se navedeno sredstvo za vezanje na stanicu bira između monoklonskih protutijela; kimernih protutijela; humaniziranih protutijela; posve ljudskih protutijela; jednolančanih protutijela; fragmenata protutijela, poput Fab, Fab′, F(ab′)2 i Fv, interferona; peptida; limfokina, poput IL-2, IL-3, IL-4, IL-6; hormona, poput inzulina, TRH (tireooslobađajućih hormona), MSH (melanostimulirajućeg hormona), steroidnih hormona, poput androgena i estrogena; čimbenika rasta i čimbenika stimulacije kolonija, poput EGF, TGFα, inzulinu sličnog čimbenika rasta (IGF-I, IGF-II) G-CSF, M-CSF i GM-CSF; vitamina, poput folata i transferina.
10. Postupak dobivanja konjugata u skladu s bilo kojim od patentnih zahtjeva 3 do 9, naznačen time što uključuje korak u kojem spoj u skladu s patentnim zahtjevom 1 koji sadrži sulfidnu, disulfidnu ili tiolnu skupinu, ili njegov preteča, reagira sa sredstvom za vezanje na stanicu, koje sadrži funkcionalnu skupinu reaktivnu prema disulfidu ili tiolu, tako da se spoj i sredstvo za vezanje na stanicu poveže zajedno preko sulfidne ili disulfidne veze.
11. Farmaceutski pripravak, naznačen time što sadrži molekulu konjugata u skladu s bilo kojim od patentnih zahtjeva 3 do 9 ili spoj u skladu s bilo kojim od patentnih zahtjeva 1 ili 2, uz farmaceutski prihvatljivu podlogu.
12. Upotreba djelotvorne količine molekule konjugata u skladu s bilo kojim od patentnih zahtjeva 3 do 9 ili spoja u skladu s bilo kojim od patentnih zahtjeva 1 ili 2, u pripravi medikamenta za ubijanje ili inhibiranje rasta stanica, naznačena time što se sastoji u stavljanju u kontakt molekule konjugata ili spoja s ciljanim stanicama ili tkivom koje sadrži ciljane stanice.
13. Upotreba djelotvorne količine molekule konjugata u skladu s bilo kojim od patentnih zahtjeva 3 do 9 ili spoja u skladu s bilo kojim od patentnih zahtjeva 1 ili 2, naznačena time što su molekula konjugata ili spoj namijenjeni pripravi medikamenta za liječenje raka.
14. Molekula konjugata namijenjena upotrebi u skladu s bilo kojim od patentnih zahtjeva 3 do 9, naznačena time što je namijenjena upotrebi kao sredstvo protiv raka.
15. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 ili 2, naznačen time što je namijenjen upotrebi kao sredstvo protiv raka.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06290154A EP1813614B1 (en) | 2006-01-25 | 2006-01-25 | Cytotoxic agents comprising new tomaymycin derivatives |
PCT/IB2007/000142 WO2007085930A1 (en) | 2006-01-25 | 2007-01-22 | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20140307T1 true HRP20140307T1 (hr) | 2014-06-20 |
Family
ID=35953949
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20110955T HRP20110955T1 (hr) | 2006-01-25 | 2011-12-19 | Citotoksična sredstva koja sadrže nove derivate tomamicina |
HRP20140307TT HRP20140307T1 (hr) | 2006-01-25 | 2014-03-31 | Citotoksiäśna sredstva koja sadrže nove derivate tomamicina i njihova upotreba u terapiji |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20110955T HRP20110955T1 (hr) | 2006-01-25 | 2011-12-19 | Citotoksična sredstva koja sadrže nove derivate tomamicina |
Country Status (39)
Country | Link |
---|---|
US (1) | US8163736B2 (hr) |
EP (4) | EP1813614B1 (hr) |
JP (1) | JP5116696B2 (hr) |
KR (1) | KR101428112B1 (hr) |
CN (1) | CN101374846B (hr) |
AR (1) | AR059201A1 (hr) |
AT (1) | ATE527262T1 (hr) |
AU (1) | AU2007209072C1 (hr) |
BR (1) | BRPI0707264A2 (hr) |
CA (1) | CA2635482C (hr) |
CR (1) | CR10149A (hr) |
CY (2) | CY1112495T1 (hr) |
DK (2) | DK1813614T3 (hr) |
DO (1) | DOP2007000016A (hr) |
EA (1) | EA017196B1 (hr) |
EC (1) | ECSP088632A (hr) |
ES (2) | ES2374964T3 (hr) |
GT (1) | GT200800147A (hr) |
HK (1) | HK1129106A1 (hr) |
HN (1) | HN2008001103A (hr) |
HR (2) | HRP20110955T1 (hr) |
IL (1) | IL192472A0 (hr) |
MA (1) | MA30226B1 (hr) |
ME (1) | ME01814B (hr) |
MX (1) | MX2008009582A (hr) |
MY (1) | MY157715A (hr) |
NI (1) | NI200800207A (hr) |
NO (1) | NO341074B1 (hr) |
NZ (1) | NZ569789A (hr) |
PE (1) | PE20071110A1 (hr) |
PL (2) | PL1813614T3 (hr) |
PT (2) | PT1813614E (hr) |
RS (2) | RS52060B (hr) |
SI (2) | SI1813614T1 (hr) |
TN (1) | TNSN08283A1 (hr) |
TW (1) | TWI389909B (hr) |
UA (1) | UA97794C2 (hr) |
WO (1) | WO2007085930A1 (hr) |
ZA (1) | ZA200805649B (hr) |
Families Citing this family (178)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA200900545B (en) | 2006-07-18 | 2010-03-31 | Sanofi Aventis | Antagonist antibody against EPHA2 for the treatment of cancer |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
EP2019104B1 (en) * | 2007-07-19 | 2013-09-04 | Sanofi | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use |
GB0819097D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
IL295601B1 (en) | 2009-02-05 | 2024-07-01 | Immunogen Inc | History of benzodiazepines and processes for their preparation |
FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
FR2949469A1 (fr) * | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
TW201116297A (en) | 2009-10-02 | 2011-05-16 | Sanofi Aventis | Antibodies that specifically bind to the EphA2 receptor |
CN105001334A (zh) | 2010-02-10 | 2015-10-28 | 伊缪诺金公司 | Cd20抗体及其用途 |
US20110256157A1 (en) * | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
CN107019804A (zh) * | 2010-04-15 | 2017-08-08 | 西雅图基因公司 | 靶向吡咯并苯并二氮杂卓结合物 |
CN102971329B (zh) | 2010-04-15 | 2016-06-29 | 麦迪穆有限责任公司 | 用于治疗增殖性疾病的吡咯并苯并二氮杂卓 |
FR2963007B1 (fr) | 2010-07-26 | 2013-04-05 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application therapeutique |
BR112013020540B1 (pt) | 2011-02-15 | 2020-12-29 | Immunogen, Inc | métodos para preparação de conjugados compreendendo agente de ligação à célula conjugado a composto citotóxico com grupo ligante |
US9156854B2 (en) | 2011-04-18 | 2015-10-13 | Immunogen, Inc. | Maytansinoid derivatives with sulfoxide linker |
US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
CA2849039C (en) * | 2011-09-20 | 2018-09-18 | Spirogen Sarl | Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates |
EP2755642B1 (en) | 2011-10-14 | 2018-07-18 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
JP6170497B2 (ja) | 2011-10-14 | 2017-07-26 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン |
US9387259B2 (en) | 2011-10-14 | 2016-07-12 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
WO2013053871A1 (en) | 2011-10-14 | 2013-04-18 | Spirogen Sàrl | Pyrrolobenzodiazepines |
CA2850371C (en) * | 2011-10-14 | 2020-06-30 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
LT2817338T (lt) | 2012-02-24 | 2017-11-10 | Abbvie Stemcentrx Llc | Dll3 moduliatoriai ir jų panaudojimo būdai |
RU2691698C2 (ru) | 2012-02-24 | 2019-06-17 | ЭББВИ СТЕМСЕНТРКС ЭлЭлСи | Антитела против sez6 и способы их применения |
AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
BR112014027166A2 (pt) | 2012-05-01 | 2017-06-27 | Genentech Inc | anticorpo, ácido nucleico, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibir proliferação e métodos de detecção. |
CN104822656B (zh) | 2012-05-15 | 2018-05-01 | 西雅图基因公司 | 自稳定接头偶联物 |
WO2013177481A1 (en) | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
BR112015000437A2 (pt) | 2012-07-09 | 2017-06-27 | Genentech Inc | imunoconjugados, formulação farmacêutica, métodos de tratamento e de inbir a proliferação de uma célula |
BR112015000441A2 (pt) | 2012-07-09 | 2017-12-19 | Genentech Inc | imunoconjugados, formulação farmacêutica e método de tratamento e método para inbir a proliferação de uma célula positiva para cd22 |
MX2015001399A (es) | 2012-08-02 | 2015-09-07 | Genentech Inc | Anticuerpos anti-etbr e inmunoconjugados. |
EP2887965A1 (en) | 2012-08-22 | 2015-07-01 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
ES2649990T3 (es) | 2012-10-12 | 2018-01-16 | Medimmune Limited | Conjugados de anticuerpos anti-CD22-pirrolobenzodiazepinas |
JP6270859B2 (ja) | 2012-10-12 | 2018-01-31 | エイディーシー・セラピューティクス・エス・アー・エール・エルAdc Therapeutics Sarl | ピロロベンゾジアゼピン−抗体結合体 |
US9745303B2 (en) | 2012-10-12 | 2017-08-29 | Medimmune Limited | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
EP2906250B1 (en) | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
WO2014057120A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
AU2013328674B2 (en) | 2012-10-12 | 2017-06-22 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
ES2703151T3 (es) | 2012-10-12 | 2019-03-07 | Adc Therapeutics Sa | Conjugados de anticuerpos de pirrolobenzodiazepinas |
KR101645905B1 (ko) | 2012-10-12 | 2016-08-04 | 스피로즌 살 | 피롤로벤조디아제핀 및 그의 컨주게이트 |
CN105102068B (zh) | 2012-10-12 | 2018-06-01 | Adc疗法责任有限公司 | 吡咯并苯并二氮杂卓-抗体结合物 |
JP6133431B2 (ja) | 2012-11-24 | 2017-05-24 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. | 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用 |
EP2745876A1 (en) | 2012-12-21 | 2014-06-25 | Prous Institute for Biomedical Research, S.A. | Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives |
BR112015014669B1 (pt) | 2012-12-21 | 2023-09-26 | Medimmune Limited | Compostos pirrolobenzodiazepinas, conjugados compreendendo os mesmos e uso destes para tratar uma doença proliferativa |
EP2935273A1 (en) | 2012-12-21 | 2015-10-28 | MedImmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
ME03394B (me) | 2013-02-22 | 2020-01-20 | Medimmune Ltd | Antidllз-antitelo-pbd konjugati i nihovа upotreba |
WO2014140862A2 (en) | 2013-03-13 | 2014-09-18 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
BR112015023070B1 (pt) * | 2013-03-13 | 2022-06-07 | Genentech, Inc. | Conjugados e compostos de pirrolobenzodiazepinas, composição farmacêutica que compreende os mesmo, bem como seus usos para o tratamento de uma doença proliferativa |
MX362970B (es) | 2013-03-13 | 2019-02-28 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
EP2970474B1 (en) | 2013-03-14 | 2017-12-20 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
TWI636792B (zh) | 2013-08-12 | 2018-10-01 | 建南德克公司 | 1-(氯甲基)-2,3-二氫-1h-苯并[e]吲哚二聚體抗體-藥物結合物化合物及使用與治療方法 |
AU2014312310A1 (en) | 2013-08-28 | 2016-04-07 | Abbvie Stemcentrx Llc | Novel SEZ6 modulators and methods of use |
AU2014312215B2 (en) | 2013-08-28 | 2020-02-27 | Abbvie Stemcentrx Llc | Site-specific antibody conjugation methods and compositions |
WO2015028850A1 (en) * | 2013-09-02 | 2015-03-05 | Hangzhou Dac Biotech Co., Ltd | Novel cytotoxic agents for conjugation of drugs to cell binding molecule |
AR097685A1 (es) | 2013-09-17 | 2016-04-06 | Genentech Inc | Métodos de uso de anticuerpos anti-lgr5 |
US9956299B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepine—antibody conjugates |
US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
WO2015052534A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
NZ717668A (en) | 2013-10-15 | 2024-03-22 | Seagen Inc | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
US10053511B2 (en) | 2013-11-06 | 2018-08-21 | Abbvie Stemcentrx Llc | Anti-claudin antibodies and methods of use |
BR112016013048A2 (pt) | 2013-12-12 | 2017-09-26 | Stemcentrx Inc | anticorpos anti-dpep3 e métodos de uso |
CA2931340A1 (en) | 2013-12-13 | 2015-06-18 | Genentech, Inc. | Anti-cd33 antibodies and immunoconjugates |
MX2016007578A (es) | 2013-12-16 | 2016-10-03 | Genentech Inc | Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento. |
KR102532137B1 (ko) | 2014-02-11 | 2023-05-12 | 씨젠 인크. | 단백질의 선택적 환원 |
PE20161209A1 (es) | 2014-02-21 | 2016-11-10 | Abbvie Stemcentrx Llc | Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma |
JP6417421B2 (ja) | 2014-02-28 | 2018-11-07 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. | 荷電連結体及び共役体のためのその使用 |
GB201406767D0 (en) | 2014-04-15 | 2014-05-28 | Cancer Rec Tech Ltd | Humanized anti-Tn-MUC1 antibodies anf their conjugates |
GB201407816D0 (en) | 2014-05-02 | 2014-06-18 | King S College London | Pyrrolobenzodiazepine Compounds |
JP2017522861A (ja) | 2014-05-22 | 2017-08-17 | ジェネンテック, インコーポレイテッド | 抗gpc3抗体及びイムノコンジュゲート |
WO2016008112A1 (en) | 2014-07-16 | 2016-01-21 | Medshine Discovery Inc. | Linkers and application towards adc thereof |
MX2017002605A (es) | 2014-08-28 | 2017-05-19 | Bioatla Llc | Receptores de antigeno quimerico condicionalmente activos para celulas t modificadas. |
RU2741470C9 (ru) * | 2014-09-02 | 2021-04-27 | Иммьюноджен, Инк. | Способы составления композиций конъюгата антитело-лекарственное средство |
TW201613930A (en) | 2014-09-03 | 2016-04-16 | Immunogen Inc | Cytotoxic benzodiazepine derivatives |
DK3189056T3 (da) | 2014-09-03 | 2020-09-14 | Immunogen Inc | Cytotoksiske benzodiazepinderivater |
TW201617368A (zh) | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗mfi2抗體及使用方法 |
WO2016037644A1 (en) | 2014-09-10 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
TW201625688A (zh) | 2014-09-12 | 2016-07-16 | 建南德克公司 | 經半胱胺酸改造之抗體及接合物 |
KR102508173B1 (ko) | 2014-09-12 | 2023-03-10 | 제넨테크, 인크. | 항-her2 항체 및 면역콘주게이트 |
CN113698485A (zh) | 2014-09-12 | 2021-11-26 | 基因泰克公司 | 抗-b7-h4抗体及免疫缀合物 |
PE20170670A1 (es) | 2014-09-12 | 2017-06-06 | Genentech Inc | Anticuerpos anti-cll-1 e inmunoconjugados |
CR20170099A (es) | 2014-09-17 | 2017-07-19 | Genentech Inc | Pirrolobenzodiazepinas y conjugados de anticuerpos-disulfuro de las mismas |
CA2957148A1 (en) | 2014-09-17 | 2016-03-24 | Genentech, Inc. | Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines |
EP3223854A1 (en) | 2014-11-25 | 2017-10-04 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
BR112017014599A2 (pt) | 2015-01-14 | 2018-01-16 | Bristol-Myers Squibb Company | dímeros de benzodiazepina, conjugados dos mesmos, e métodos de preparação e uso |
BR112017014937A2 (pt) | 2015-01-14 | 2018-03-13 | Bristol-Myers Squibb Company | dímeros de benzodiazepina ligados em ponte a heteroarileno, conjugados dos mesmos, e métodos de preparação e uso |
US9504694B2 (en) | 2015-03-19 | 2016-11-29 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepines |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
GB201506389D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
MX2017015814A (es) | 2015-06-23 | 2018-04-10 | Squibb Bristol Myers Co | Dimeros de benzodiazepina macrociclica, conjugados de los mismos, preparacion y usos. |
CN113350518A (zh) | 2015-07-12 | 2021-09-07 | 杭州多禧生物科技有限公司 | 与细胞结合分子的共轭偶联的桥连接体 |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
HUE051541T2 (hu) | 2015-07-21 | 2021-03-01 | Immunogen Inc | Eljárások citotoxikus benzodiazepin származékok elõállítására |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
SG11201807827VA (en) | 2016-03-25 | 2018-10-30 | Seattle Genetics Inc | Process for the preparation of pegylated drug-linkers and intermediates thereof |
KR102606938B1 (ko) | 2016-04-15 | 2023-11-29 | 바이오아트라, 인코퍼레이티드 | 항 Axl항체 및 이의 면역접합체와 이것들의 용도 |
WO2017184942A1 (en) | 2016-04-21 | 2017-10-26 | Abbvie Stemcentrx Llc | Novel anti-bmpr1b antibodies and methods of use |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
WO2017196847A1 (en) | 2016-05-10 | 2017-11-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens |
TW201808336A (zh) | 2016-05-11 | 2018-03-16 | 賽諾菲公司 | 用抗muc1類美登素免疫綴合物抗體治療腫瘤的治療方案 |
AU2017263568B2 (en) | 2016-05-13 | 2024-01-18 | Bioatla, Llc | Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof |
JP7022080B2 (ja) | 2016-05-27 | 2022-02-17 | ジェネンテック, インコーポレイテッド | 部位特異的抗体-薬物複合体の特徴付けのための生化学分析的方法 |
WO2017214182A1 (en) | 2016-06-07 | 2017-12-14 | The United States Of America. As Represented By The Secretary, Department Of Health & Human Services | Fully human antibody targeting pdi for cancer immunotherapy |
AU2017305170A1 (en) | 2016-08-02 | 2019-02-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof |
MX2019001302A (es) | 2016-08-09 | 2019-06-12 | Seattle Genetics Inc | Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas. |
WO2018031662A1 (en) | 2016-08-11 | 2018-02-15 | Genentech, Inc. | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
EP3538080A4 (en) | 2016-11-14 | 2020-07-08 | Hangzhou Dac Biotech Co., Ltd. | CONJUGATION LINERS, MEDICAMENT-MOLECULE CONJUGATES TO A CELL CONTAINING THE SAME, METHODS OF PREPARING AND USING SUCH CONJUGATES WITH THE BINDERS |
AU2017361887B2 (en) | 2016-11-21 | 2019-08-15 | Cureab Gmbh | Anti-GP73 antibodies and immunoconjugates |
JP7244987B2 (ja) | 2016-12-14 | 2023-03-23 | シージェン インコーポレイテッド | 多剤抗体薬物コンジュゲート |
US11236171B2 (en) | 2016-12-21 | 2022-02-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for FLT3 and uses thereof |
US11384098B2 (en) | 2017-02-08 | 2022-07-12 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
ES2871001T3 (es) | 2017-02-08 | 2021-10-28 | Adc Therapeutics Sa | Conjugados de pirrolobenzodiazepinas y anticuerpos |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
CA3056134A1 (en) | 2017-03-24 | 2018-09-27 | Seattle Genetics, Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
RS63502B1 (sr) | 2017-04-18 | 2022-09-30 | Medimmune Ltd | Konjugati pirolobenzodiazepina |
US20200129637A1 (en) | 2017-04-20 | 2020-04-30 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
US20180346488A1 (en) | 2017-04-20 | 2018-12-06 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and conjugates thereof |
AU2018268970A1 (en) | 2017-05-19 | 2019-10-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibody targeting tnfr2 for cancer immunotherapy |
US11318211B2 (en) | 2017-06-14 | 2022-05-03 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
WO2019005208A1 (en) | 2017-06-30 | 2019-01-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY |
CA3066953A1 (en) | 2017-06-30 | 2019-01-03 | Lentigen Technology, Inc. | Human monoclonal antibodies specific for cd33 and methods of their use |
DK3668874T3 (da) | 2017-08-18 | 2022-02-14 | Medimmune Ltd | Pyrrolobenzodiazepin-konjugater |
KR20220156974A (ko) | 2017-09-20 | 2022-11-28 | 주식회사 피에이치파마 | 타일란스타틴 유사체 |
IL301637B1 (en) | 2017-09-29 | 2024-06-01 | Daiichi Sankyo Co Ltd | Conjugation of an antibody with a pyrrolobenzodiazepine derivative |
BR112020008676A2 (pt) * | 2017-11-02 | 2020-10-27 | Ube Industries, Ltd. | composto, e, composição farmacêutica. |
WO2019096788A1 (en) | 2017-11-14 | 2019-05-23 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US11793885B2 (en) | 2017-12-28 | 2023-10-24 | Immunogen, Inc. | Substituted benzo[5,6][1,4]diazepino[1,2-a]indoles for the treatment of proliferative disorders |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) * | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
JP2021525265A (ja) | 2018-05-25 | 2021-09-24 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン複合体 |
AU2019301675A1 (en) | 2018-07-12 | 2021-01-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Affinity matured CD22-specific monoclonal antibody and uses thereof |
EP3829647A1 (en) | 2018-07-31 | 2021-06-09 | Astrazeneca AB | Linkers and conjugates |
WO2020033430A1 (en) | 2018-08-08 | 2020-02-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity monoclonal antibodies targeting glypican-2 and uses thereof |
CA3112977A1 (en) | 2018-10-19 | 2020-04-23 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
KR20210081350A (ko) | 2018-10-19 | 2021-07-01 | 메드임뮨 리미티드 | 피롤로벤조디아제핀 컨쥬게이트 |
GB201820725D0 (en) | 2018-12-19 | 2019-01-30 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine resistance |
WO2020127573A1 (en) | 2018-12-19 | 2020-06-25 | Adc Therapeutics Sa | Pyrrolobenzodiazepine resistance |
EP3898693A4 (en) | 2018-12-21 | 2022-09-21 | Avidity Biosciences, Inc. | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF |
US20220096641A1 (en) * | 2019-01-03 | 2022-03-31 | Legochem Biosciences, Inc. | Pyrrolobenzodiazepine dimer compound with improved safety and use thereof |
CN113490510A (zh) | 2019-01-08 | 2021-10-08 | 美国政府(由卫生和人类服务部的部长所代表) | 用于治疗实体瘤的靶向间皮素的跨物种单结构域抗体 |
US20220098323A1 (en) | 2019-01-22 | 2022-03-31 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | High affinity monoclonal antibodies targeting glypican-1 and methods of use |
WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
BR112021018260A2 (pt) | 2019-03-15 | 2021-11-23 | Medimmune Ltd | Dímeros de azetidobenzodiazepina e conjugados compreendendo-os para uso no tratamento de câncer |
DK3946464T3 (da) | 2019-03-29 | 2022-10-31 | Medimmune Ltd | Forbindelser og konjugater deraf |
JP2022529583A (ja) | 2019-03-29 | 2022-06-23 | イミュノジェン・インコーポレーテッド | 異常細胞増殖を阻害するまたは増殖性疾患を治療するための細胞毒性ビス-ベンゾジアゼピン誘導体及び細胞結合剤とのその複合体 |
GB201908128D0 (en) | 2019-06-07 | 2019-07-24 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
CN110483504B (zh) * | 2019-08-02 | 2022-04-26 | 桂林理工大学 | 以DMF为甲酰化试剂构建2-(2-萘基)咪唑[1,2-a]吡啶-3-醛的新方法 |
WO2021074392A1 (en) * | 2019-10-16 | 2021-04-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Visual detection of pbd induced dna crosslinks |
JP2022552875A (ja) | 2019-10-22 | 2022-12-20 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 多様な固形腫瘍を処置するためのb7h3(cd276)を標的とする高親和性ナノボディ |
WO2021080608A1 (en) | 2019-10-25 | 2021-04-29 | Medimmune, Llc | Branched moiety for use in conjugates |
EP4041769A1 (en) | 2019-12-12 | 2022-08-17 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Antibody-drug conjugates specific for cd276 and uses thereof |
TW202140076A (zh) | 2020-01-22 | 2021-11-01 | 英商梅迪繆思有限公司 | 化合物及其軛合物 |
WO2021148500A1 (en) | 2020-01-22 | 2021-07-29 | Medimmune Limited | Compounds and conjugates thereof |
WO2021188390A1 (en) | 2020-03-19 | 2021-09-23 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
IL296393A (en) | 2020-03-27 | 2022-11-01 | Avidity Biosciences Inc | Preparations and methods for the treatment of muscle atrophy |
CN115955980A (zh) | 2020-04-10 | 2023-04-11 | 思进公司 | 电荷可变接头 |
US20230391852A1 (en) | 2020-10-26 | 2023-12-07 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting sars coronavirus spike protein and uses thereof |
US12036286B2 (en) | 2021-03-18 | 2024-07-16 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
IL305886A (en) | 2021-03-18 | 2023-11-01 | Seagen Inc | Selective release of drugs from internalized conjugates of biologically active compounds |
GB202105186D0 (en) | 2021-04-12 | 2021-05-26 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
GB202105187D0 (en) | 2021-04-12 | 2021-05-26 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
WO2022232612A1 (en) | 2021-04-29 | 2022-11-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Lassa virus-specific nanobodies and methods of their use |
CN117500831A (zh) | 2021-06-09 | 2024-02-02 | 美国政府(由卫生和人类服务部的部长所代表) | 用于治疗实体瘤的靶向pd-l1的跨物种单结构域抗体 |
WO2023288252A1 (en) | 2021-07-13 | 2023-01-19 | Truebinding, Inc. | Methods of preventing protein aggregation |
GB202110726D0 (en) | 2021-07-26 | 2021-09-08 | Cambridge Entpr Ltd | Conjugating reagents and conjugates thereof |
CA3231330A1 (en) | 2021-09-16 | 2023-03-23 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
TW202406934A (zh) | 2022-05-03 | 2024-02-16 | 美商建南德克公司 | 抗Ly6E抗體、免疫結合物及其用途 |
GB202207691D0 (en) | 2022-05-25 | 2022-07-06 | Cambridge Entpr Ltd | Quinone protected forms and conjugates |
WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1516743A (fr) | 1966-04-01 | 1968-02-05 | Rhone Poulenc Sa | Nouvel antibiotique et son procédé de préparation par culture de streptomyces croceus |
US4625014A (en) | 1984-07-10 | 1986-11-25 | Dana-Farber Cancer Institute, Inc. | Cell-delivery agent |
US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
US4764368A (en) | 1984-08-29 | 1988-08-16 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
WO1991013080A1 (en) | 1990-02-20 | 1991-09-05 | Gilead Sciences, Inc. | Pseudonucleosides and pseudonucleotides and their polymers |
ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
EP1193270B1 (en) | 1998-08-27 | 2003-05-14 | Spirogen Limited | Pyrrolobenzodiazepines |
GB9818731D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
US6472056B1 (en) | 1999-07-06 | 2002-10-29 | Northwest Coatings Corp. | Radiation-cured laminate label |
EP1242401B1 (en) | 1999-11-24 | 2006-12-27 | Immunogen, Inc. | Cytotoxic agents comprising taxanes and their therapeutic use |
DE60142286D1 (de) * | 2000-06-16 | 2010-07-15 | Dept Of Radiation Oncology Uni | Methode zu der konditionierung einer saüle mit avidin oder streptavidin matrix in einer vorrichtung ausserhalb des körpers |
US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
DE60324607D1 (de) * | 2003-03-31 | 2008-12-18 | Council Scient Ind Res | Pyrrolo(2,1-c)(1,4)benzodiazepin-dimere als antitumormittel und verfahren dafür |
CR20170291A (es) | 2003-05-20 | 2017-07-27 | Immunogen Inc | Agentes citotoxicos mejorados que comprenden nuevos maitansinóides |
GB0416511D0 (en) * | 2003-10-22 | 2004-08-25 | Spirogen Ltd | Pyrrolobenzodiazepines |
AU2004284075A1 (en) | 2003-10-22 | 2005-05-06 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto |
GB0404578D0 (en) * | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
US7528126B2 (en) | 2004-03-09 | 2009-05-05 | Spirogen Limited | Pyrrolobenzodiazepines |
GB0410725D0 (en) * | 2004-05-13 | 2004-06-16 | Spirogen Ltd | Pyrrolobenzodiazepine therapeutic agents |
-
2006
- 2006-01-25 PL PL06290154T patent/PL1813614T3/pl unknown
- 2006-01-25 ES ES06290154T patent/ES2374964T3/es active Active
- 2006-01-25 AT AT06290154T patent/ATE527262T1/de active
- 2006-01-25 RS RS20110579A patent/RS52060B/en unknown
- 2006-01-25 PT PT06290154T patent/PT1813614E/pt unknown
- 2006-01-25 SI SI200631216T patent/SI1813614T1/sl unknown
- 2006-01-25 EP EP06290154A patent/EP1813614B1/en active Active
- 2006-01-25 DK DK06290154.1T patent/DK1813614T3/da active
-
2007
- 2007-01-19 DO DO2007P000016A patent/DOP2007000016A/es unknown
- 2007-01-22 SI SI200731435T patent/SI1981889T1/sl unknown
- 2007-01-22 ZA ZA200805649A patent/ZA200805649B/xx unknown
- 2007-01-22 CN CN200780003379XA patent/CN101374846B/zh active Active
- 2007-01-22 ME MEP-2014-39A patent/ME01814B/me unknown
- 2007-01-22 ES ES07700505.6T patent/ES2457525T3/es active Active
- 2007-01-22 MX MX2008009582A patent/MX2008009582A/es active IP Right Grant
- 2007-01-22 DK DK07700505.6T patent/DK1981889T3/da active
- 2007-01-22 CA CA2635482A patent/CA2635482C/en not_active Expired - Fee Related
- 2007-01-22 PT PT77005056T patent/PT1981889E/pt unknown
- 2007-01-22 BR BRPI0707264-3A patent/BRPI0707264A2/pt not_active IP Right Cessation
- 2007-01-22 EP EP10180643A patent/EP2371827A1/en not_active Withdrawn
- 2007-01-22 NZ NZ569789A patent/NZ569789A/en not_active IP Right Cessation
- 2007-01-22 UA UAA200810591A patent/UA97794C2/ru unknown
- 2007-01-22 KR KR1020087020594A patent/KR101428112B1/ko active IP Right Grant
- 2007-01-22 JP JP2008551898A patent/JP5116696B2/ja active Active
- 2007-01-22 EA EA200870193A patent/EA017196B1/ru not_active IP Right Cessation
- 2007-01-22 RS RS20140168A patent/RS53293B/en unknown
- 2007-01-22 WO PCT/IB2007/000142 patent/WO2007085930A1/en active Application Filing
- 2007-01-22 EP EP07700505.6A patent/EP1981889B1/en active Active
- 2007-01-22 MY MYPI20082798A patent/MY157715A/en unknown
- 2007-01-22 TW TW096102368A patent/TWI389909B/zh not_active IP Right Cessation
- 2007-01-22 EP EP10180637A patent/EP2386559A1/en not_active Withdrawn
- 2007-01-22 PL PL07700505T patent/PL1981889T3/pl unknown
- 2007-01-22 AU AU2007209072A patent/AU2007209072C1/en not_active Ceased
- 2007-01-24 PE PE2007000074A patent/PE20071110A1/es not_active Application Discontinuation
- 2007-01-24 AR ARP070100311A patent/AR059201A1/es not_active Application Discontinuation
-
2008
- 2008-06-23 TN TNP2008000283A patent/TNSN08283A1/en unknown
- 2008-06-26 IL IL192472A patent/IL192472A0/en not_active IP Right Cessation
- 2008-07-14 HN HN2008001103A patent/HN2008001103A/es unknown
- 2008-07-16 CR CR10149A patent/CR10149A/es not_active Application Discontinuation
- 2008-07-16 US US12/174,195 patent/US8163736B2/en active Active
- 2008-07-18 EC EC2008008632A patent/ECSP088632A/es unknown
- 2008-07-22 GT GT200800147A patent/GT200800147A/es unknown
- 2008-07-24 NI NI200800207A patent/NI200800207A/es unknown
- 2008-08-05 NO NO20083427A patent/NO341074B1/no not_active IP Right Cessation
- 2008-08-19 MA MA31188A patent/MA30226B1/fr unknown
-
2009
- 2009-08-10 HK HK09107327.0A patent/HK1129106A1/xx not_active IP Right Cessation
-
2011
- 2011-12-19 HR HR20110955T patent/HRP20110955T1/hr unknown
- 2011-12-29 CY CY20111101291T patent/CY1112495T1/el unknown
-
2014
- 2014-03-31 HR HRP20140307TT patent/HRP20140307T1/hr unknown
- 2014-04-14 CY CY20141100277T patent/CY1115199T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20140307T1 (hr) | Citotoksiäśna sredstva koja sadrže nove derivate tomamicina i njihova upotreba u terapiji | |
HRP20120067T1 (hr) | Citotoksična sredstva koja sadrže nove derivate tomamicina i njihova upotreba u terapiji | |
RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения | |
HRP20191169T1 (hr) | Konjugati antidll3-protutijelo-pbd i njihove uporabe | |
AU2013229786B2 (en) | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof | |
CN106029083B (zh) | 亲水性抗体-药物偶联物 | |
JP2016531914A5 (hr) | ||
JP6282745B2 (ja) | 修飾抗上皮成長因子受容体抗体およびその使用法 | |
JP2016531915A5 (hr) | ||
HRP20161050T1 (hr) | Her2/neu specifična protutijela i postupci njihovog korištenja | |
JP7191938B2 (ja) | Igf-1rモノクローナル抗体及びその使用 | |
KR20200033306A (ko) | 생체 내 내성이 높은 항체 약물 결합체 | |
JP2016536020A5 (hr) | ||
RU2010145177A (ru) | Лекарственное средство для лечения рака печени | |
CN110799540B (zh) | 多特异性抗体及其制备和使用方法 | |
KR20160099711A (ko) | 키네신 스핀들 단백질(ksp)과의 항체 약물 접합체 (adcs) | |
KR20170054430A (ko) | 세포-결합제 및 세포독성 약물을 포함하는 콘주게이트 | |
JP2017537893A5 (hr) | ||
CN104244718A (zh) | 抗体-药物缀合物以及相关化合物、组合物和方法 | |
JP2014506120A5 (hr) | ||
JP2009500005A5 (hr) | ||
JP2017500028A5 (hr) | ||
JP2013518912A5 (hr) | ||
WO2017161206A1 (en) | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use | |
CN117065043A (zh) | 防止免疫结合物中的甲硫氨酸氧化的方法 |